Overview

Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Participants who have completed the 3-week trial P05691 (NCT00764478) can be screened for eligibility for this 26-week extension study in which they will continue treatment. The primary purpose of this trial is to evaluate the long-term safety of asenapine.
Phase:
Phase 3
Details
Lead Sponsor:
Forest Laboratories
Treatments:
Asenapine